Kruis 2019.

Study name	Novel rifamycin Sv multi‐matrix formulation for treatment of acute uncomplicated diverticulitis: results of a prospective double‐blind, placebo‐controlled, randomized study
Methods	Randomised controlled trial, quadruple‐blinded (participant, care provider, investigator, outcomes assessor)
Participants	201
Interventions	Rifamycin 400 mg vs. rifamycin 600 mg vs. placebo (controls)
Outcomes	Primary: Treatment success at day 10 Secondary: Complete treatment success
Starting date	August 2013
Contact information	Not noted
Notes	Completed July 2017